We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Kymera Therapeutics Inc
1 own
3 watching
Current Price
$23.38
$-1.98
(-7.81%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,292.36M
52-Week High
39.85
52-Week Low
13.15
Average Volume
0.75M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,292.36M52-Week High39.8552-Week Low13.15Average Volume0.75MDividend Yield--P/E Ratio--What does the Kymera Therapeutics Inc do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More
How much money does Kymera Therapeutics Inc make?
News & Events about Kymera Therapeutics Inc.
Market News Video
1month ago
In trading on Thursday, shares of Kymera Therapeutics Inc (KYMR) crossed below their 200 day moving average of 29.07, changing hands as low as 26.43 per share. Kymera Therapeutics Inc shares are currently trading down about 13.4% on the day...
InvestorPlace
2 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.
The post 7 Biotech Stocks to Buy for 100% Returns appeared first on InvestorPlace...
Zolmax
3 months ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) has earned an average rating of Hold from the eleven brokerages that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The ...
Globe Newswire
5 months ago
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the 41st Annual J.P...
Frequently Asked Questions
Frequently Asked Questions
What is Kymera Therapeutics Inc share price today?
Can Indians buy Kymera Therapeutics Inc shares?
How can I buy Kymera Therapeutics Inc shares from India?
Can Fractional shares of Kymera Therapeutics Inc be purchased?
What are the documents required to start investing in Kymera Therapeutics Inc stocks?
What is today’s traded volume of Kymera Therapeutics Inc?
What is today’s market capitalisation of Kymera Therapeutics Inc?
What is the 52-Week High and Low Range of Kymera Therapeutics Inc?
What percentage is Kymera Therapeutics Inc down from its 52-Week High?
What percentage is Kymera Therapeutics Inc up from its 52-Week Low?
Current Price
$23.38
$-1.98
(-7.81%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.